vidarabine has been researched along with Infections, Roseolovirus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartelink, IH; Bierings, MB; Boelens, JJ; de Wildt, A; Gerhardt, CE; Lindemans, CA; van Maarseveen, EM; van Reij, EM; Versluys, B | 1 |
| Jackson, GH; Nicolle, AL; Stark, GL; Taylor, CE; Wipat, W | 1 |
2 other study(ies) available for vidarabine and Infections, Roseolovirus
| Article | Year |
|---|---|
Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.
Topics: Adenoviridae Infections; Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Lung; Male; Myeloablative Agonists; Roseolovirus Infections; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Human herpesvirus 6 encephalitis following flag chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Encephalitis, Viral; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Herpesvirus 6, Human; Humans; Immunocompromised Host; Male; Middle Aged; Opportunistic Infections; Roseolovirus Infections; Vidarabine | 2003 |